Click here to return to the Reference Table

Category: Carcinomas
Cancer type: Gastric
Descriptor: Reviews

Reference Number: 382
Bachleitner-Hofmann T, Sun MY, Chen CT, Tang L, Song L, Zeng Z, Shah M, Christensen JG, Rosen N, Solit DB, Weiser MR HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther. 7, 3499-508 (2008)
PubMed link      E-mail link

Reference Number: 621
Corso S, Ghiso E, Cepero V, Sierra JR, Migliore C, Bertotti A, Trusolino L, Comoglio PM, Giordano S. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer. 26, 121 (2010)
PubMed link      E-mail link

Reference Number: 1520
Teng L, Lu J. cMET as a potential therapeutic target in gastric cancer (Review). Int J Mol Med. 32, 1247-54 (2013)
PubMed link      E-mail link

Reference Number: 1596
Al-Batran SE, Werner D Recent advances and future trends in the targeted therapy of metastatic gastric cancer. Expert Rev Gastroenterol Hepatol. 8, 555-69 (2014)
PubMed link      E-mail link

Reference Number: 1613
Hack SP, Bruey JM, Koeppen H. HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development. Oncotarget. 5, 2866-80 (2014)
PubMed link      E-mail link

Reference Number: 1693
Venerito M, Nardone G, Selgrad M, Rokkas T, Malfertheiner P. Gastric cancer--epidemiologic and clinical aspects. Helicobacter. 19, Suppl 1:32-7 (2014)
PubMed link      E-mail link

Reference Number: 1711
Thiel A, Ristimäki A. Targeted therapy in gastric cancer. APMIS. 123, 365-72 (2015)
PubMed link      E-mail link

Reference Number: 1728
Abdel-Rahman O Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications. Expert Rev Anticancer Ther. 15,235-45 (2015)
PubMed link      E-mail link

Reference Number: 1742
Marano L, Chiari R, Fabozzi A, De Vita F, Boccardi V, Roviello G, Petrioli R, Marrelli D, Roviello F, Patriti A. c-Met targeting in advanced gastric cancer: An open challenge. Cancer Lett. 365, 30-6 (2015)
PubMed link      E-mail link

Reference Number: 1837
Aprile G, Ongaro E, Del Re M, Lutrino SE, Bonotto M, Ferrari L, Rihawi K, Cardellino GG, Pella N, Danesi R, Fasola G. Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight. Crit Rev Oncol Hematol. 95, 165-78 (2015)
PubMed link      E-mail link

Reference Number: 1854
Kim C, Mulder K, Spratlin J. How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer. Oncologist. 19, 1046-55 (2014)
PubMed link      E-mail link